Oncopeptides withdraws withdrawal of first marketed drug


24 January 2022 - Swedish pharmaceutical company Oncopeptides announced that it has contacted the U.S FDA and rescinded its 22 October 22 2021 letter requesting voluntary withdrawal of the NDA of Pepaxto (melphalan flufenamide) in the United States.

Oncopeptides has discontinued the marketing of Pepaxto, also called melflufen, in the U.S and does not intend to market Pepaxto in the U.S. at this time.

Read BioSpace article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US , Withdrawal